Bitcoin groundbreakers share personal stories of how Bitcoin is changing lives for the better. Host Mauricio Di Bartolomeo, co-founder and CSO of Ledn, speaks with leading Bitcoin voices, entrepreneurs, and human rights advocates to hear their unique journey and practical real-world examples of how Bitcoin has made a positive impact in their lives. Brought to you by Ledn, a leading financial services company built for Bitcoin & digital assets. Ledn offers a suite of lending, saving and tradi ...
…
continue reading
Konten disediakan oleh Proactive Investors. Semua konten podcast termasuk episode, grafik, dan deskripsi podcast diunggah dan disediakan langsung oleh Proactive Investors atau mitra platform podcast mereka. Jika Anda yakin seseorang menggunakan karya berhak cipta Anda tanpa izin, Anda dapat mengikuti proses yang diuraikan di sini https://id.player.fm/legal.
Player FM - Aplikasi Podcast
Offline dengan aplikasi Player FM !
Offline dengan aplikasi Player FM !
Nanoviricides investigates NV-387 for MPOX treatment amid global outbreak
MP3•Beranda episode
Manage episode 438988245 series 2891889
Konten disediakan oleh Proactive Investors. Semua konten podcast termasuk episode, grafik, dan deskripsi podcast diunggah dan disediakan langsung oleh Proactive Investors atau mitra platform podcast mereka. Jika Anda yakin seseorang menggunakan karya berhak cipta Anda tanpa izin, Anda dapat mengikuti proses yang diuraikan di sini https://id.player.fm/legal.
Nanoviricides CEO Dr Anil Diwan joined Steve Darling from Proactive to discuss the company's exploration of using its antiviral candidate, NV-387, for the treatment of MPOX patients under the World Health Organization's (WHO) MEURI protocol. This comes in response to the 2024 MPOX outbreak, which is rapidly spreading across more than ten African countries, with additional cases reported in Thailand and Sweden. Dr. Diwan explained that NV-387 has already completed Phase I clinical trials for safety and tolerability, with no adverse events reported, indicating excellent safety. The compound has shown strong survival improvement in animal models, performing on par with the currently approved drug tecovirimat, demonstrating significant potential for effectiveness. As MPOX Clade 1/1b strains demand the development of new therapeutics due to limitations in existing treatments, NV-387 could play a critical role. In an animal model study simulating direct skin infection, the primary mode of MPOX transmission, NV-387 was as effective as tecovirimat, highlighting its promise as a novel broad-spectrum antiviral treatment. #proactiveinvestors #nanoviricidesinc #nyseamerican #nnvc #NV387 #VirusTreatment #Antiviral #mPox #Biotechnology #RSV #Influenza #ClinicalTrials #HealthcareInnovation #ProactiveInvestors #PharmaceuticalResearch#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
…
continue reading
605 episode
MP3•Beranda episode
Manage episode 438988245 series 2891889
Konten disediakan oleh Proactive Investors. Semua konten podcast termasuk episode, grafik, dan deskripsi podcast diunggah dan disediakan langsung oleh Proactive Investors atau mitra platform podcast mereka. Jika Anda yakin seseorang menggunakan karya berhak cipta Anda tanpa izin, Anda dapat mengikuti proses yang diuraikan di sini https://id.player.fm/legal.
Nanoviricides CEO Dr Anil Diwan joined Steve Darling from Proactive to discuss the company's exploration of using its antiviral candidate, NV-387, for the treatment of MPOX patients under the World Health Organization's (WHO) MEURI protocol. This comes in response to the 2024 MPOX outbreak, which is rapidly spreading across more than ten African countries, with additional cases reported in Thailand and Sweden. Dr. Diwan explained that NV-387 has already completed Phase I clinical trials for safety and tolerability, with no adverse events reported, indicating excellent safety. The compound has shown strong survival improvement in animal models, performing on par with the currently approved drug tecovirimat, demonstrating significant potential for effectiveness. As MPOX Clade 1/1b strains demand the development of new therapeutics due to limitations in existing treatments, NV-387 could play a critical role. In an animal model study simulating direct skin infection, the primary mode of MPOX transmission, NV-387 was as effective as tecovirimat, highlighting its promise as a novel broad-spectrum antiviral treatment. #proactiveinvestors #nanoviricidesinc #nyseamerican #nnvc #NV387 #VirusTreatment #Antiviral #mPox #Biotechnology #RSV #Influenza #ClinicalTrials #HealthcareInnovation #ProactiveInvestors #PharmaceuticalResearch#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
…
continue reading
605 episode
All episodes
×Selamat datang di Player FM!
Player FM memindai web untuk mencari podcast berkualitas tinggi untuk Anda nikmati saat ini. Ini adalah aplikasi podcast terbaik dan bekerja untuk Android, iPhone, dan web. Daftar untuk menyinkronkan langganan di seluruh perangkat.